Using patient-derived organoids to predict locally advanced or metastatic lung cancer tumor response: A real-world study

Predicting the clinical response to chemotherapeutic or targeted treatment in patients with locally advanced or metastatic lung cancer requires an accurate and affordable tool. Tumor organoids are a potential approach in precision medicine for predicting the clinical response to treatment. However, their clinical application in lung cancer has rarely been reported because of the difficulty in generating pure tumor organoids. In this study, we have generated 214 cancer organoids from 107 patients, of which 212 are lung cancer organoids (LCOs), primarily derived from malignant serous effusions. LCO-based drug sensitivity tests (LCO-DSTs) for chemotherapy and targeted therapy have been performed in a real-world…

• NN
  National Natural Science Foundation of China

  Award: 81972164
• NS
  Natural Science Foundation of Guangdong Province

  Award: 2019A1515010931
• UD
  Universidade de Macau
• HH
  High-level Hospital Construction Project of Guangdong Provincial People's Hospital

  Award: DFJH201809